• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种HIV细胞融合抑制剂T22([酪氨酸5,12,赖氨酸7] - 海螯虾抗菌肽II)的高效低细胞毒性类似物

Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II).

作者信息

Tamamura H, Arakaki R, Funakoshi H, Imai M, Otaka A, Ibuka T, Nakashima H, Murakami T, Waki M, Matsumoto A, Yamamoto N, Fujii N

机构信息

Graduate School of Pharmaceutical Sciences, Kyoto University, Japan.

出版信息

Bioorg Med Chem. 1998 Feb;6(2):231-8. doi: 10.1016/s0968-0896(97)10037-2.

DOI:10.1016/s0968-0896(97)10037-2
PMID:9547946
Abstract

A tachyplesin peptide analog, T22 ([Tyr5,12, Lys7]-polyphemusin II), and its shortened congener, TW70 (des-[Cys8,13, Tyr9,12]-[D-Lys10, Pro11]-T22) have strong anti-human immunodeficiency virus (HIV) activity, comparable to that of 3'-azido-2', 3'-dideoxythymidine (AZT). T22 and TW70 are extremely basic peptides, containing 5 Arg residues and 3 Lys residues. The number of positive charges might be related in part to high collateral cytotoxicities of T22 and TW70. Here we have synthesized several analogs, in which the number of positive charges has been reduced through amino acid substitutions using Glu or L-citrulline. As a result, several effective compounds have been found which possess higher selectivity indexes (SIs, 50% cytotoxic concentration/50% effective concentration) than those of T22 and TW70. Higher SIs were attributed mainly to a decrease in cytotoxicity.

摘要

一种鲎抗菌肽类似物T22([酪氨酸5,12,赖氨酸7]-鲎素II)及其缩短的同类物TW70(去-[半胱氨酸8,13,酪氨酸9,12]-[D-赖氨酸10,脯氨酸11]-T22)具有很强的抗人类免疫缺陷病毒(HIV)活性,与3'-叠氮-2',3'-双脱氧胸苷(AZT)相当。T22和TW70是极具碱性的肽,含有5个精氨酸残基和3个赖氨酸残基。正电荷的数量可能部分与T22和TW70的高附带细胞毒性有关。在此,我们合成了几种类似物,其中通过使用谷氨酸或L-瓜氨酸进行氨基酸取代来减少正电荷的数量。结果,发现了几种有效的化合物,它们具有比T22和TW70更高的选择性指数(SI,50%细胞毒性浓度/50%有效浓度)。更高的SI主要归因于细胞毒性的降低。

相似文献

1
Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II).一种HIV细胞融合抑制剂T22([酪氨酸5,12,赖氨酸7] - 海螯虾抗菌肽II)的高效低细胞毒性类似物
Bioorg Med Chem. 1998 Feb;6(2):231-8. doi: 10.1016/s0968-0896(97)10037-2.
2
Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure.一种HIV细胞融合抑制剂T22([酪氨酸5,12,赖氨酸7] - 海胆精蛋白II)的缩微化,同时保持抗HIV活性和溶液结构。
Bioorg Med Chem. 1998 Apr;6(4):473-9. doi: 10.1016/s0968-0896(97)10055-4.
3
Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.鲎素类似物对CXCR4的结合能力增强,导致抗HIV活性以及对CXCR4介导的HIV进入的抑制活性显著增加。
AIDS Res Hum Retroviruses. 1999 Mar 20;15(5):419-27. doi: 10.1089/088922299311169.
4
Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.一种特异性CXCR4抑制剂T140的药效团鉴定,促成了具有非常高选择性指数的有效抗HIV药物的研发。
Bioorg Med Chem Lett. 2000 Dec 4;10(23):2633-7. doi: 10.1016/s0960-894x(00)00535-7.
5
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II).一种新型抗HIV合成肽,T-22([酪氨酸5,12,赖氨酸7] - 多聚半胱氨酸II)
Biochem Biophys Res Commun. 1992 Dec 15;189(2):845-50. doi: 10.1016/0006-291x(92)92280-b.
6
Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.趋化因子受体(CXCR4)拮抗剂T22([酪氨酸(5,12),赖氨酸7] - 多聚半胱氨酸II)的药效团鉴定,该拮抗剂可特异性阻断T细胞系嗜性HIV-1感染。
Bioorg Med Chem. 1998 Jul;6(7):1033-41. doi: 10.1016/s0968-0896(98)00061-3.
7
Structure-activity relationships of an anti-HIV peptide, T22.抗HIV肽T22的构效关系
Biochem Biophys Res Commun. 1994 Dec 30;205(3):1729-35. doi: 10.1006/bbrc.1994.2868.
8
Molecular parameters for the anti-human immunodeficiency virus activity of T22 ([Tyr5,12, Lys7]-polyphemusin II).T22([酪氨酸5,12,赖氨酸7] - 海螯虾抗菌肽II)抗人类免疫缺陷病毒活性的分子参数
Biol Pharm Bull. 1994 Dec;17(12):1669-72. doi: 10.1248/bpb.17.1669.
9
Analysis of the interaction of an anti-HIV peptide, T22 ([Tyr5, 12, Lys7]-polyphemusin II), with gp120 and CD4 by surface plasmon resonance.通过表面等离子体共振分析抗HIV肽T22([酪氨酸5,12,赖氨酸7]-海胆精蛋白II)与gp120和CD4的相互作用。
Biochim Biophys Acta. 1996 Nov 14;1298(1):37-44. doi: 10.1016/s0167-4838(96)00113-6.
10
A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance.通过核磁共振对鲎素I和一种新型抗HIV合成肽T22([酪氨酸5,12,赖氨酸7] - 海胆精蛋白II)的溶液结构进行的比较研究。
Biochim Biophys Acta. 1993 May 13;1163(2):209-16. doi: 10.1016/0167-4838(93)90183-r.

引用本文的文献

1
The Diphtheria Toxin Translocation Domain Impairs Receptor Selectivity in Cancer Cell-Targeted Protein Nanoparticles.白喉毒素转位结构域损害癌细胞靶向蛋白纳米颗粒中的受体选择性。
Pharmaceutics. 2022 Nov 29;14(12):2644. doi: 10.3390/pharmaceutics14122644.
2
The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies.多组氨酸标签H6介导崩解性、蛋白质释放型包涵体的结构和功能特性。
Pharmaceutics. 2022 Mar 10;14(3):602. doi: 10.3390/pharmaceutics14030602.
3
Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials.
肿瘤靶向蛋白-MMAE纳米共轭物从可植入混合材料中的长时间释放
Pharmaceutics. 2022 Jan 14;14(1):192. doi: 10.3390/pharmaceutics14010192.
4
Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4.肿瘤标志物CXCR4的特异性肽配体T22的抗菌活性
Pharmaceutics. 2021 Nov 13;13(11):1922. doi: 10.3390/pharmaceutics13111922.
5
Ion-dependent slow protein release from disintegrating micro-granules.离子依赖性崩解微丸的缓慢蛋白释放。
Drug Deliv. 2021 Dec;28(1):2383-2391. doi: 10.1080/10717544.2021.1998249.
6
Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors.CXCR4 靶向 HIV-1 进入抑制剂的发现和发展。
Exp Biol Med (Maywood). 2020 Mar;245(5):477-485. doi: 10.1177/1535370220901498. Epub 2020 Feb 4.
7
The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.CXCR4表达与前列腺癌临床病理意义及潜在药物靶点的关联:一项荟萃分析与文献综述
Drug Des Devel Ther. 2015 Sep 7;9:5115-22. doi: 10.2147/DDDT.S82475. eCollection 2015.
8
The intricate role of CXCR4 in cancer.CXCR4在癌症中的复杂作用。
Adv Cancer Res. 2014;124:31-82. doi: 10.1016/B978-0-12-411638-2.00002-1.
9
PET imaging of CXCR4 receptors in cancer by a new optimized ligand.利用新型优化配体对癌症中CXCR4受体进行正电子发射断层扫描成像
ChemMedChem. 2011 Oct 4;6(10):1789-91. doi: 10.1002/cmdc.201100320. Epub 2011 Jul 20.
10
Retrocyclins and their activity against HIV-1.回旋蛋白酶抑制剂及其抗 HIV-1 活性。
Cell Mol Life Sci. 2011 Jul;68(13):2231-42. doi: 10.1007/s00018-011-0715-5. Epub 2011 May 7.